Koers Novus Therapeutics, Inc. Nasdaq
Aandelen
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | 33,33 mln. 31,12 mln. | Marktkapitalisatie | 102 mln. 94,91 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -47 mln. -43,88 mln. | Nettowinst (verlies) 2025 * | -33 mln. -30,81 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,05 x |
K/w-verhouding 2024 * |
-2,04
x | K/w-verhouding 2025 * |
-4,24
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,49% |
Recentste transcriptie over Novus Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 51 | 01-05-20 | |
Paul Little
DFI | Director of Finance/CFO | 60 | 15-03-21 |
Steven Perrin
PSD | President | 59 | 14-09-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Keith Katkin
CHM | Chairman | 52 | 01-05-17 |
Walter Ogier
BRD | Director/Board Member | 67 | 14-09-20 |
John McBride
BRD | Director/Board Member | 72 | 01-05-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,20% | 121 mld. | |
+19,67% | 113 mld. | |
+18,95% | 26,02 mld. | |
-23,86% | 19,39 mld. | |
-19,03% | 15,91 mld. | |
-20,90% | 15,09 mld. | |
-46,14% | 15,06 mld. | |
+63,85% | 14,93 mld. | |
+4,49% | 13,85 mld. |